3. Highlights 2016-2017
GreenPeak - divestment
Gimv and other investors sell their interest in Dutch semiconductor company GreenPeak to Nasdaq-listed Qorvo.
G-Therapeutics - investment
EUR 6 million investment - as part of a total EUR 26 million series A funding - in Swiss company G-Therapeutics, which is developing a spinal implant neurostimulator for patients with incomplete transverse lesion (partial paraplegia).
Joolz - investment
Gimv acquires 40% interest in the fast-growing Joolz, a Dutch brand of premium children's pushchairs.
Arplas - investment
Investment in the further growth of Arplas, a Dutch supplier of innovative welding technology, operating especially in the automotive industry.
EndoStim - investment
USD 2.7 million investment - as part of a total USD 25 million series D funding - in EndoStim, a Dutch medtech company that has designed a neurostimulator for patients with gastroesophageal reflux (GERD).
Vandemoortele - divestment
Gimv sells its 23.58% share in Vandemoortele, a family-controlled Belgian food group with a European dimension, to Safinco.
Real Impact Analytics - investment
Real Impact Analytics, a Belgian innovative startup in big data applications, obtains EUR 12 million from Gimv and other investors in its first funding round.
Lampiris - divestment
Gimv and the other shareholders sell their interests in Belgian energy distributor Lampiris to Total.
Brakel - follow-on investment
Gimv investee Brakel, a Dutch company in high-end solutions and ventilation and fire safety systems for commercial and industrial buildings, strengthens its fire safety division by acquiring Belgian company Argina Technics.
Summa - investment
Gimv invests in the further international growth of Belgian company Summa, a European leader in digital cutting machineryfor the graphics industry.
Punch Powertrain - divestment
Sale of Punch Powertrain, the Belgian pioneer of continuously variable transmission technology (CVT), to the Chinese group Yinyi.
Spineart - investment
Gimv and Gimv Health & Care Fund provide EUR 30 million of growth capital to Spineart, a fast-growing Swiss medtech company active in spinal cord surgery.
Acceo - investment
Gimv acquires a 60% stake in Acceo, a French independent player in building inspection and certification services.
MEGA International - investment
With a 40% shareholding, Gimv invests in the next growth phase of MEGA International, a leading French provider of software for business and IT transformations.
Multiplicom - divestment
Gimv and Biotech Fund Flanders sell Belgian molecular diagnostics company Multiplicom to Agilent Technologies.
Itineris - follow-on investment
Gimv and Gimv-managed Gimv Arkiv Tech Fund II together invest EUR 7.8 million in Itineris, a Belgian supplier of innovative software solutions, to accelerate the company's further international growth.
Breath Therapeutics - investment
Breath Therapeutics raises EUR 43.5 million in a financing round co-led by Gimv. This German spin-out of PARI Pharma GmbH is committed to progressive and innovative inhalation therapies for severe respiratory tract disorders.
Teads - divestment
Gimv announces the sale of French Teads, the inventor of outstream video advertising and the largest video advertising platform in the world, to listed company Altice.